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Cholestatic jaundice in early infancy is a complex diagnostic problem. Misdiagnosis of
cholestasis as physiologic jaundice delays the identification of severe liver diseases. In
the majority of infants, prolonged physiologic jaundice represent benign cases of breast
milk jaundice, but few among them are masked and caused by neonatal cholestasis (NC)
that requires a prompt diagnosis and treatment. Therefore, a prolonged neonatal jaundice,
longer than 2weeks after birth, must always be investigated because an early diagnosis
is essential for appropriate management. To rapidly identify the cases with cholestatic
jaundice, the conjugated bilirubin needs to be determined in any infant presenting with
prolonged jaundice at 14 days of age with or without depigmented stool. Once NC is
confirmed, a systematic approach is the key to reliably achieve the diagnosis in order
to promptly initiate the specific, and in many cases, life-saving therapy. This strategy is
most important to promptly identify and treat infants with biliary atresia, the most common
cause of NC, as this requires a hepatoportoenterostomy as soon as possible. Here, we
provide a detailed work-up approach including initial treatment recommendations and
a clinically oriented overview of possible differential diagnoses in order to facilitate the
early recognition and a timely diagnosis of cholestasis. This approach warrants a broad
spectrum of diagnostic procedures and investigations including new methods that are
described in this review.
Keywords: neonatal cholestasis, neonatal jaundice, conjugated hyperbilirubinemia, biliary atresia, kasai procedure
Abbreviations: AFP, alpha-fetoprotein; ALL, acute lymphoblastic leukemia; ALP, alkaline phosphatase; ALT, alanine amino-
transferase; AML, acute myeloid leukemia; ANA, anti-nuclear antibodies; ARPKD, autosomal recessive polycystic kidney
disease; AST, aspartate transaminase; ATIII, antithrombin III; α1AT, α1-antitrypsin; BA, biliary atresia; BM, bone marrow;
BSEP, bile salt export pump; CDG, congenital disorders of glycosylation; CESD, cholesterol ester storage disease; CF, cystic
fibrosis; CMV, cytomegalovirus; CrP, C-reactive protein; ECG, electrocardiogram; ERCP, endoscopic retrograde cholan-
giopancreatography; GALD, gestational alloimmune liver disease; GGT, gamma-glutamyltransferase; HCC, hepatocellular
carcinoma; HIV, human immunodeficiency virus; HDL, high-density lipoprotein; HLH, hemophagocytic lymphohistiocytosis;
HSV, herpes simplex virus; IEF, isoelectrofocusing; IGF, insuline-like growth factor; IGFBP, insuline-like growth factor
binding protein; IVIG, intravenous immunoglobulin; LCS1, lymphedema cholestasis syndrome1; LDH, lactate dehydrogenase;
LDL, low-density lipoprotein; LIPA, lysosomal lipase acid; MCP, medium chain triglycerides; MRCP, magnetic resonance
cholangiopancreatography imaging; MRI, magnetic resonance imaging; NAFLD, non-alcoholic fatty liver disease; NGCH,
idiopathic neonatal giant cell hepatitis; NICCD, citrin deficiency; NPD, Niemann–Pick disease; OXSPHOS, respiratory chain
oxidative phosphorylation; PBMC, peripheral blood mononuclear cells; PCR, polymerase chain reaction; PFIC, progressive
familiary intrahepatic cholestasis; PNAC, parenteral nutrition-associated cholestasis; PNALD, parenteral nutrition-associated
liver disease; PTT, partial thromboplastin time; SMA, smooth muscle antibody; TNP, total parenteral nutrition; TSH,
thyroid-stimulating hormone; US, ultrasonography; VLCFA, very long chain fatty acids.
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Introduction
Neonatal physiological jaundice is a common and mostly benign
symptom. It typically resolves 2weeks after birth. Neonatal
cholestasis (NC), however, indicated by a conjugated hyperbiliru-
binemia, is never benign and indicates the presence of a severe
underlying condition. A defect of the intrahepatic production or
the transmembrane transport of bile, or a mechanical obstruction
preventing bile flow leads to an accumulation of bile components
in the liver, in the blood and extrahepatic tissues. The incidence
of NC is ~1 in 2500 live births (1). Of the various conditions
that can present with NC, biliary atresia (BA) represents the
major cause and has been reported to occur in 35–41% of the
cases followed by progressive familial intrahepatic cholestasis
(PFIC) (10%), preterm birth (10%), metabolic and endocrino-
logical disorders (9–17%), Alagille syndrome (AS) (2–6%), infec-
tious diseases (1–9%), mitochondriopathy (2%), biliary sludge
(2%), and, finally, idiopathic cases (13–30%) (2, 3). The rapid
diagnosis of BA is paticularly important because early surgical
intervention by hepatoportoenterostomy before 2months of age
correlates with better long-term outcome (4–8). Unfortunately,
the diagnosis of NC is often delayed and the average age at
diagnosis of BA is about 60 days in USA and Germany (9, 10).
For these reasons, the fractionated bilirubin must be determined
in any infant presenting with prolonged jaundice lasting longer
for 14 days of age for term and 21 days for preterm infants with
or without depigmented stool. Once conjugated hyperbilirubine-
mia is identified, a systematic approach is the key to reliably
achieve a rapid diagnosis, so that the specific and often life-saving
therapy can be promptly initiated. This review offers not only a
systematic diagnostic approach but also highlights new diagnostic
techniques that have decreased the proportion of idiopathic cases
in favor of previously under-reported conditions, such as PFIC,
bile acid synthesis defects, and mitochondrial disorders (2). The
most frequent causes of NC are discussed and rare congenital
infectious or neonatal disorders are summarized in an adjacent
table.
A Diagnostic Approach to NC and
Recommendations for Initial Management
In cases of prolonged neonatal jaundice, the fractionated bilirubin
needs to be determined as a first step (Figure 1). A conjugated
bilirubin of more than 1mg/dL in combination with a total biliru-
bin of <5.0mg/dL, or a conjugated bilirubin fraction of >20%
of the total, if total bilirubin is >5.0mg/dL, indicates NC. A
parenteral report of depigmented feces suggests an extrahepatic
obstructive process. For clarification, the stool should be seen by
a physician in any case.
First of all, conditions or complications that require immediate
treatment should be detected. Therefore, a series of basic blood
tests need to be performed (as listed at the bottom of Figure 1).
Further important initial steps are a fasting ultrasonography, a
liver biopsy, and a hepatobiliary scintigraphy. If these tests are
inconclusive, then the next step is to undertake an intraoper-
ative cholangiogram or ERCP. In some cases, the liver biopsy
may need to be repeated 3–4months after birth, because several
of the diseases follow a dynamic course (11, 12). In patients
with advanced disease, insufficient hepatic synthetic function
and hypovitaminosis, a vitamin K-dependent bleeding disorder
may occur. Therefore, an oral supplementation with vitamin
K (1mg/day), vitamin A (1500U/kg/day), vitamin D (cholecal-
ciferol; 500U/kg/day), and vitamin E (50U/kg/day) should be
initiated immediately.
Disorders Causing Neonatal Cholestasis
Obstructive Bile Duct Disorders
Biliary atresia is the most frequent and severe cause of NC.
In a few cases, it may be part of a syndrome and associated
with other congenital malformations such as polysplenia (100%),
situs inversus (50%), or cardiac anomalies (50%) and/or vascular
malformations, e.g., preduodenal portal vein (60%) (13).
Biliary atresia is an ascending inflammatory process of the
biliary tree leading to progressive obliterative scarring of the extra-
hepatic and intrahepatic bile ducts, resulting in biliary cirrhosis
(14).Only early surgical treatment can stall biliary cirrhosis, which
is why rapid identification of BA is crucial.
The exact etiopathogenesis of BA is still unknown and is sug-
gested to involve environmental, infectious, and genetic factors
(15). In murine models, pre- or perinatal infections with rotavirus
(16, 17), cytomegalovirus (15), and reovirus (18) were shown
to infect and damage bile duct epithelia giving support to the
hypothesis of a primary cholangiotropic viral infection as the
initiating event of BA. In humans, however, studies focusing on
the detection of viral infections at the time of diagnosis have
produced conflicting results (19). In addition, alloimmune events
mediated by liver infiltrating maternal effector T lymphocytes
(microchimerism) have also been proposed to play a part in the
pathogenesis of BA (20).
Infants with BA present with a conjugated hyperbilirubinemia,
elevated liver transaminases including GGT and depigmented or
pale stool. An abdominal ultrasound should be performed early to
exclude other extrahepatic obstructive lesions such as choledochal
cysts, gallstones, or bilary cast. The finding of a small or even
absent gallbladder is suggestive of BA. In the majority of the
cases, the presence of a structure15mm in length located in the
expected region showing irregularmargins without a well-defined
wall excludes a normal gallbladder (21). A pre- and postprandial
ultrasonography facilitates the demonstration of a physiologic gall
bladder contraction. A triangular periportal echogenic structure
(>3mm in thickness) in the liver hilum is called the “triangular-
cord-sign,” a finding associated with high sensitivity (73–100%)
and specificity (98–100%) of BA (22, 23). In addition, assessing
the hepatic arterial subcapsular flow by color Doppler ultrasonog-
raphy has recently been reported to enable the discrimination of
BA from other causes of NC (24).
The diagnostic gold standard of BA is a percutaneous liver
biopsy followed by an intraoperative cholangiogram if inconclu-
sive (11). Liver biopsy leads to the diagnosis in 79–98% of cases
(25). Histology is characterized by inflammatory cell infiltrates
around bile ducts, portal tract fibrosis, accumulation of bile typ-
ically presenting as bile plugs, and bile duct proliferation. ERCP
may serve as a reliable and safe additional diagnostic tool (10,
26, 27) exhibiting a sensitivity of up to 86–92% and a speci-
ficity of 73–94% (10, 28). Hepatobiliary sequence scintigraphy is
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FIGURE 1 | Diagnostic algorithm for neonatal cholestasis. After
confirming direct hyperbilirubinemia, biliary atresia as the most frequent
disorder must rapidly be excluded. Hence, the abdominal ultrasound
examination (fasting) is of central importance for the evaluation of a
cholestatic infant and should be obtained as early as possible. Liver
structure, size, dilated bile ducts, gall bladder (size, wall thickness, triangular
cord sign), identification of extrahepatic obstructive lesions (e.g., choledochal
cyst, gallstones, sludge), ascites, spleen size, situs abnormalities, and
vascular malformations should be determined by an experienced operator. If
feces is not depigmented and the ultrasound examination remains
inconclusive, the diagnostic procedure needs to be quickly expanded as
indicated in the text box on the lower right.
associated with a high sensitivity (83–100%) but lacks specificity
in many cases (33–80%), limiting its usefulness to discriminate
between BA and other non-surgical conditions (29). Additional
non-invasive and other quite promising studies focus on the
identification of serum markers that may reliably distinguish
BA from other forms of NC (30, 31). Song et al. (30) found
that the expression of the apolipoproteins Apo C-II and Apo C-
III to be upregulated in the serum of infants with BA, while
Zahm et al. (31) analyzed elevated patterns of circulating micro-
RNAs and identified the miR-200b/429 cluster as a potential
biomarker.
Treatment of BA consists of a hepatoportoenterostomy to
enable biliary drainage (32). The success rate of this procedure is
closely associated with the age of the infant at time of surgery (4,
7–9).Most reliable predictors for successful surgery and long-term
outcome with the native liver are the normalization of conjugated
bilirubin and AST 2months after surgery (33). Although the
problem of late diagnosis has been defined for some years, surgery
within the first 2months of age has still not been universally
achieved in many centers/countries (9, 10, 34). In Taiwan, a stool
color card system led to a decline of late referral (35), which is
one reason why it is regarded as a simple and promising screening
approach to early the identification of BA (36).
Alagille syndrome accounts for 2–6% of infants with NC (2, 3).
Liver histology typically demonstrates a paucity of interlobular
biliary ducts. Bile ductular proliferation as observed in BA is
absent. Mutations in the JAG-1 gene are responsible formore than
90% of cases of AS; others have mutations in the gene encoding
for the NOTCH-2 receptor (37, 38). The main diagnostic criteria
of AS are typical facial signs such as a broad forehead, deep set
eyes, and a pointed chin giving the face a triangular appearance
(77–98%), an ocular embryotoxon (61–88%), cardiac abnormal-
ities (85–97%), and butterfly vertebrae (39–87%). Minor criteria
are growth (50–87%) and/or developmental delay (16–52%), renal
disease such as renal cysts, renal artery stenosis, and tubular aci-
dosis (40–73% cases), and exocrine pancreatic insufficiency (40%)
(39, 40). Early development of hepatocellular carcinoma (HCC)
may occur regardless of the presence of cirrhosis. Thus, patients
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with AS should be screened for HCC with alpha-fetoprotein and
ultrasonography every 6months.
Cystic, ectatic alterations of the intra- and/or extrahepatic bile
duct system represent a further cause of NC. Choledochal cysts
account for 2–3% of infants with NC and are surgically treat-
able (2). According to Todani, five anatomic variants have been
described, but most infants show dilatation of the common bile
duct (Todani type 1, 50–80% of biliary cysts) (41). Caroli’s disease
is associated with multifocal, segmental, and saccular or fusiform
dilatations of themediumand large intrahepatic bile ductswithout
affecting the common bile duct (28). Thesemalformationsmay be
limited to one liver lobe,most commonly the left one. Involvement
of both the medium intrahepatic bile ducts (Caroli’s disease) and
the small interlobular bile ducts results in themore frequentCaroli
syndrome. Caroli syndrome is associated with ciliopathies and fre-
quently presents with congenital hepatic fibrosis. This condition
may also include renal abnormalities, e.g., autosomal recessive
polycystic kidney disease (ARPKD), juvenile nephronophtisis,
Joubert syndrome, and others (42). The diagnosis is established
by ultrasound, ERCP, and/or MRCP (28). Administration of
ursodeoxycholic acid (UDCA) decreases bile stasis and prevents
the formation of intrahepatic cholelithiasis. Liver transplantation
is a curative therapy (43).
Neonatal onset of sclerosing cholangitis is characterized at ERCP
by a varying degree of stenotic and focally dilated intrahepatic bile
ducts with rarification of segmental branches (44, 45). Liver trans-
plantation is the only treatment option. In a few cases, it is asso-
ciated with ichthyosis, and hence termed as neonatal ichthyosis
and sclerosing cholangitis (NISCH) syndrome. NISCH is caused
by mutations of the CLDN1 gene encoding for Claudin-1, a tight-
junction protein. The Claudin-1 defect leads to an increased para-
cellular permeability andhepatocellular damage caused by toxicity
of paracellular bile regurgitation (46).
Idiopathic neonatal giant cell hepatitis is a differential diagnosis
after exclusion of all other causes of NC (47). Histology findings
are non-specific, and include the formation of syncytial multi-
nucleated hepatic giant cells, variable inflammation, with infil-
tration of lymphocytes, neutrophils, and eosinophils and lobular
cholestasis – changes that are also seen in other conditions, such
as α1ATD or PFIC (47).
The non-cholestatic entities Dubin-Johnson syndrome (defect
in the MRP2 gene) (48) and Rotor syndrome (defect in the
OATP1B1/OATP1B3 gene) (49) need to be distinguished from
NC. These conditions also manifest with direct hyperbilirubine-
mia but the excretion of serum bile acid is unimpaired. In
Dubin–Johnson syndrome, biliary excretion of conjugated biliru-
bin via the MRP-2 channel is impaired, whereas in Rotor syn-
drome, there is a defect in the hepatic storage of conjugated
bilirubin, which then leaks into the plasma. Diagnosis and dif-
ferentiation between these conditions are achieved by urinary
coproporphyrin analysis (50, 51).
Alterations in the Hepatocellular Bile Acid
Transport System
The PFIC conditions are a heterogeneous group of autosomal
recessive disorders characterized by mutations in hepatocellu-
lar bile acid transport-system genes leading to impaired bile
formation. About 10% of infants that present with NC suffer from
PFIC-1 and -2 (2). Three types of PFIC have been identified:
PFIC1 and PFIC2 usually appear in the first months of life,
whereas onset of PFIC3 typically arises later in childhood. Infants
with PFIC1 or PFIC2 present with NC, therapy resistant pruritus
and coagulopathy due to vitamin K malabsorption. A charac-
teristic feature of these conditions is that the serum gamma-
glutamyltransferase activity is normal or even low in PFIC1 and
PFIC2 patients, but elevated in PFIC3 patients. PFIC1 is caused
by impaired bile salt secretion due to defects in the ATP8B1
gene that encodes the FIC1 protein – a protein that stabilizes
the hepatocellular membrane by transfer of aminophospholipids
(52). Mutations in the FIC1 gene also cause benign recurrent
intrahepatic cholestasis (BRIC1, Summerskill syndrome), which
is characterized by recurrent episodes of cholestasis that may not
necessarily lead to liver cirrhosis (53). Mutations in the ABCB11
gene encoding the bile salt export pump (BSEP) protein lead to
PFIC2 (52, 54). Defects in ABCB4 that encodes the multidrug
resistance 3 protein (MDR3) impair biliary phospholipid secretion
and result in PFIC3 (52, 55). Diagnosis is based on immunos-
taining of BSEP (PFIC2) and MDR3 (PFIC3) in liver biopsies as
well as the analysis of biliary lipid composition and genotyping
for PFImutations causing PFIC1. UDCAhelps to postpone biliary
cirrhosis in the PFIC conditions. An early partial external biliary
diversion normalizes serum bile acids and relieves pruritus for
childrenwith PFIC1 and 2 (56). This procedure decelerates disease
progression until liver transplantation is needed.
Metabolic Disorders and Storage Diseases
Neonatal cholestasis is caused by a number of metabolic disor-
ders with cystic fibrosis (CF) and alpha-1-antitrypsin deficiency
(α1ATD) being the most common. Although infants with CF
are more likely to present with meconium ileus or steatorrhea
with failure to thrive, 5% of patients with CF manifest with NC
(57). α1ATD is inherited in an autosomal recessive trait and,
similarly to CF, estimated to affect 1 in 2500–5000 children (58).
The proportion of infants with α1ATD in cases of NC is about
1–17% (2, 3). A pathologic polymerization of AAT within the
endoplasmatic reticulum results in an intrahepatocellular accu-
mulation of the misfolded α1AT molecule leading to progre-
dient liver fibrosis/cirrhosis. Hence, serum α1AT concentration
is typically decreased. However, a normal α1AT level does not
exclude the diagnosis because α1AT is an acute phase protein and
may be raised by inflammatory processes. Therefore, the deficient
α1AT-variant needs to be identified by protease inhibitor (PI)
typing using polyacrylamide isoelectric focusing (59). While liver
involvement in childhood is mainly associated with the PI-ZZ
genotype (60), the PI-MZ and PI-SZ types are both characterized
by respiratory symptoms (e.g., recurrent pneumothoraces) (61).
The pathogenesis of the pulmonary manifestation differs from
liver disease. In the lung, severe deficiency of the elastase inhibitor
AAT results in an uninhibited proteolytic activity of elastase pre-
disposing to a chronic obstructive disease with development of
a panacinar emphysema. However, within the first two decades
of life, liver dysfunction represents the major threat whereas pul-
monary disease in not a major concern (62). Liver transplantation
is curative and the treatment of choice for α1ATD.
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TABLE 1 | Summary of the differential diagnoses and diagnostic approaches.
Disease Diagnostic approach Genetic analysis
BILE DUCT OBSTRUCTION
Structural
Biliary atresia US, liver biopsy, ERCP, hepatobiliary scintigraphy, intraoperative cholangiogram Wildhaber (71), Mieli-Vergani and Vergani (4)
Alagille syndrome Typical facial features, chest x-ray (butterfly vertebrae), ophthalmology, echo, liver
biopsy, cholesterol "
JAG1, NOTCH2 genes; Vajro et al. (39),
Turnpenny and Ellard (40), Kamath et al. (38)
Choledochal cyst US, ERCP, MRCP Todani et al. (41)
Caroli’s disease/syndrome US (liver and kidneys), ERCP, MRCP if >1 year of age, PKHD1 gene (ARPKD) Adeva et al. (72), Harring et al. (43), Krall
et al. (73)
Gallstones or biliary sludge US, ERCP
Neonatal sclerosing
cholangitis
ERCP, liver biopsy Baker et al. (44), Girard et al. (45)
Hepatocellular
Idiopathic neonatal giant cell
hepatitis (NGCH)
Histological diagnosis after exclusion of other causes Torbenson (47)
Progressive familial
intrahepatic cholestasis (PFIC)
Liver biopsy, genetic analysis ABCB4, ABCB11, ATP8B1; Jacquemin (52),
Kubitz et al. (54)
GGT (#–! in types 1+2, " in type 3)
METABOLIC DISORDERS, STORAGE DISEASES, AND OTHERS
Cystic fibrosis Newborn screening (not in Germany), trypsinogen content in stool, genetic analysis CFTR gene; Sokol and Durie (57)
A1AT deficiency A1AT levels # SERPINA1 gene analysis for prenatal
diagnosis; Perlmutter (59), Fregonese and
Stolk (58)
PI analysis (type ZZ, SZ, MZ)
Inborn errors of bile acid
synthesis
Urinary bile acid analysis, molecular–genetic analysis Clayton et al. (66); BAAT and SLC27A5
gene, Setchell et al. (67)
Gaucher disease AP ", β-glucocerebrosidase #, chitotriosidase ", BM biopsy: “crinkled paper”
cytoplasm and glycolipid-laden macrophages, foam cells (Gaucher cells)
Rosenbloom et al. (69)
Niemann–Pick type C Filipin positive reaction (detection of cholesterol in fibroblasts), genetic testing,
chitotriosidase "
NPC1, NPC2 gene; Patterson et al.(74)
Wolman disease, LAL
deficiency
Lysosomal lipase acid ## in PBMC LIPA gene; Zhang and Porto (75)
Mitochondrial disorders Fasting and postprandial lactate, plasma lactate/pyruvate ratio >20, functional
assays, genetics
SCO1, SUCLG1, BCS1L, POLG1,
C10ORF2, DGUOK, and MPV17 gene
mutations; Fellman and Kotarsky (76), Wong
et al. (77)
Neonatal Intrahepatic
cholestasis caused by citrin
deficiency (NICCD)
Citrulline ", α-fetoprotein ", and ferritin" SLC25A13 gene; Lu et al. (78), Kimura et al.
(79), Song et al. (80)
Peroxismal disorders
(Zellweger’s spectrum and
others)
Zellweger’s: Typical craniofacial dysmorphism, mental retardation, hepatomegaly,
glomerulocystic kidney disease, cataracts, pigmentary retinopathy
Moser et al. (81, 82)
VLCFA ", pattern of plasmalogenes, phytanic acid, pristanic acid
Tyrosinemia Newborn screening, urinary excretion of succinylacetone ", 4-hydroxy-
phenylketones, and δ-aminolevulinic acid" Cave: HCC (AFP") (83)
FAH gene, de Laet et al. (84)
Classic galactosemia Newborn screening, galactose-1-phosphate uridyl transferase activity in red blood
cells ##
Mayatepek et al. (85)
Congenital disorders of
glycosylation (CDG)
Dysmorphic facies, convergent strabism, inverted mammils, mental retardation,
seizures, dystrophy, hepatomegaly, hepatic fibrosis/steatosis, cyclic vomiting and
diarrhea, coagulopathy, protein losing enteropathy with hypoalbuminemia (CDG1b)
Jaeken (86), Freeze (87, 88), Linssen
et al. (89)
Lab chemistry: Triglycerides ", ATIII #, factor XI #, protein C and S #, Transferrin IEF
ENDOCRINE DISORDERS
Hypothyroidism Newborn screening (TSH ") Hanna et al. (90)
Panhypopituitarism Glucose #, Cortisol #, TSH #, fT4 #, IGF1 #, IGFBP # Binder et al. (91), Karnsakul et al. (92)
TOXIC OR SECONDARY DISORDERS
Parenteral
nutrition-associated
cholestasis (PNAC), drugs
(e.g., anticonvulsants)
Exclusion of other causes Hsieh et al. (93)
(Continued)
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TABLE 1 | Continued
Disease Diagnostic approach Genetic analysis
IMMUNOLOGICAL DISORDERS
Gestational alloimmune liver
disease (GALD)
Ferritin "" (>1000µg/L), buccal mucosal biopsy and liver biopsy (iron deposition?),
MRI (extrahepatic iron deposition?)
Rand et al. (94)
Neonatal lupus
erythematosus
Transplacental passage of ANA, anti-RoSSA, anti-La/SSB, anti-U1RNP antibodies Hon and Leung (95)
Echo, ECG (congenital heart block)
Haemophagocytic
lymphohistiocytosis (HLH)
Fever (>7days), hepatosplenomegaly with liver dysfunction, pancytopenia, sCD25
(>2400µg/mL), ferritin (>500µg/L), triglycerides (>3mmol/L), hypofibrinogenemia
(<150mg/dL), serum cytokine levels of both IFNg (>75pg/ml) + IL-10 (>60pg/ml) "
Lehmberg and Ehl (96), Xu et al. (97)
INFECTIOUS DISORDERS
Sepsis, urinary tract
infections, TORCH, hepatitis
A–E, EBV, HIV, Echo, adeno,
coxsackie virus, Parvo B19,
HHV6-8, VZV, syphilis,
leptospirosis
PCR, microbiology, serology, ophthalmologic examination (toxoplasmosis, CMV,
rubella)
Kosters and Karpen (98), Bellomo-Brandao
et al. (99), Robino et al. (100)
VASCULAR MALFORMATIONS
Portosystemic shunts US, MRI, LE", unexplained galactosemia, hyperammonemia, manganemia Bernard et al. (101)
Multiple hemangioma US, MRI Avagyan et al. (102), Horii et al. (103)
Congestive heart failure Echo (heart anomalies, e.g., in Down syndrome), US, liver histology Arnell and Fischler (104)
MISCELLANEOUS
Genetic disorders Trisomy 21, Trisomy 18
ARC syndrome Arthrogryposis multiplex congenita, facial dysmorphia, dystrophia, renal tubular
acidosis, cholestasis, platelet dysfunction, ichthyosis
VPS33B gene; Smith et al. (105), Eastham
et al. (106)
Aagenes syndrome Lymphedema cholestasis syndrome 1 (LCS1) Drivdal et al. (107)
Microvillus inclusion disease
(MVID)
Life threatening congenital watery diarrhea of secretory type. Histology: microvillus
atrophy, detection of PAS+ granules and CD10+ lining in LM and inclusion bodies
in EM
MYO5B gene, Ruemmele et al. (108)
Neonatal leukemia AMLALL Van der Linden et al. (109)
AFP, alpha-fetoprotein; ALP, alkaline phosphatase; BM, bone marrow; DD, differential diagnosis; ERCP, endoscopic retrograde cholangiopancreaticography; EM, electronmicroscopy;
HCC, hepatocellular carcinoma; MRI, magnetic resonance imaging; LE, liver enzymes; LM, light microscopy; PBMC, peripheral blood mononuclear cell; US, ultrasound; VLCFA, very
long chain fatty acids.
Inherited disorders of bile acid synthesis cause ~2% of persistent
cholestasis in infants (63). Cholestasis is thought to result from
an imbalance and inadequate production of primary bile acids.
This results in an accumulation of aberrant hepatotoxic bile acids
and intermediary metabolites leading to an impaired bile flow
(64). In contrast to other causes of NC, the serum bile acid
levels are normal. Enzyme defects result in a specific pattern of
metabolites that can be assessed by analysis of urinary cholanoids
(bile acids and bile alcohols) (65, 66). Molecular–genetic anal-
ysis of the genes encoding the bile acid-CoA amino acid N-
acyltransferase (BAAT) and bile acid-CoA ligase (SLC27A5) is
possible (67). Peroral treatment with primary bile acids (cholic
acid, not UDCA) leads to normalization of liver function in most
patients (68).
Storage disorders and disorders of lipid metabolism, includ-
ing Gaucher disease and Niemann–Pick type C disease (NPD),
contribute to ~1% of infants with NC (2). In Gaucher dis-
ease, deficiency of the lysosomal β-glucocerebrosidase results in
the impaired recycling of cellular glycolipids. The consequence
is an excessive storage of glucocerebroside in the liver, lung,
spleen, bone, and bone marrow (69). Infants develop anemia,
thrombocytopenia, hepatosplenomegaly, and, in some cases, bone
infarcts and aseptic bone necrosis. Therapeutic options for type I
Gaucher disease are an enzyme-replacement therapy or a substrate
reduction therapy with oral Miglustat that inhibits the gluco-
sylceramide synthase (70). The diagnostic procedures for the
confirmation of Gaucher disease and NPD are summarized in
Table 1.
Wolman disease and cholesterol ester storage disease (CESD) are
rare autosomal recessive disorders with an estimated incidence
of 1 in 40,000 live births (75). Their identification is espe-
cially important as an enzyme-replacement therapy with human
recombinant lysosomal acid lipase (LAL) is now available and
improves the natural course, thus offering a possibility for long-
term survival (78, 79). Wolman disease may manifest as NC,
and clinically appears within the first 2–4months of age with
hepatosplenomegaly, liver fibrosis, adrenal calcification and insuf-
ficiency, malabsorption, diarrhea, and poor weight gain as com-
mon features. Wolman disease usually takes a fatal course,
with death within 12months of age. Both diseases result from
a deficiency of the LAL that usually catalyzes the degrada-
tion of cholesteryl esters and triglycerides that are delivered to
the liposomes by a LDL-receptor mediated endocytosis. LAL-
deficiency thus leads to elevated serum triglycerides and LDL,
an intralysosomal accumulation of cholesteryl esters, triglyc-
erides, and other lipids in various tissues, predominantly in
macrophages. Whereas a loss of function mutation in the LIPA
gene causes Wolman disease, CESD results when residual activity
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of the LAL enzyme is retained. Symptoms of CESD may be non-
specific in early infancy. It is felt that the incidence of CESD is
currently underestimated as it easily can be misdiagnosed as non-
alcoholic fatty liver disease (NAFLD) later in childhood (75). Both
entities show microvesicular steatosis on liver histology. Identifi-
cation of Maltese cross-type birefringence (stored liquid crystals
of cholesteryl esters) on frozen sections, and/or the detection of
the lysosomal-associated membrane proteins 1 and 2 (LAMP)
around the lipid droplets suggest CESD (110). Diagnosis is based
on LIPA gene sequencing and assessment of LAL levels in PBMCs
(111).
Mitochondrial disorders manifesting early in life often have
a hepatic involvement, and in the majority of cases more than
one organ such as the muscle or the nervous system is affected
(76). A recent study reported that ~2% of infants with NC suffer
from a mitochondrial hepatopathy (2). Clinical manifestations
and the degree of organ involvement varies. This condition often
remains undetected until exacerbation is precipitated, typically
following an intercurrent viral infection. Histological findings
include glycogen deprivation of the hepatocytes, microvesicular
lipid accumulation, and signs of fibrosis/cirrhosis. Among the
mitochondriopathies, Pearson syndrome is most often presents
with liver manifestations (76). The diagnostic work-up should
include genetic testing as well as functional assessment of the
respiratory chain enzyme complexes in both liver and muscle
biopsies (77). Of note, liver injury caused by any NC can secon-
darily affect OXPHOS activity. As a consequence, a compromised
mtDNA complex activity may, therefore, not necessarily serve as
proof for a mitochondriopathy related liver disease. Further rare
metabolic causes are summarized in Table 1.
Conclusion
A variety of disorders can present with cholestasis during the
neonatal period. In all cases of neonatal jaundice lasting longer
than 14 days, the measurement of fractionated bilirubin must be
performed. BA is the most common entity leading to NC. It
must be differentiated from other causes of cholestasis promptly
because early surgical intervention before 2months of age results
in a better patient outcome. Previously underdiagnosed disor-
ders comprise the PFICs, hepatic mitochondriopathies, and also,
presumably, the LAL deficiency that causes Wolman disease and
CESD. Early identification of the possible disorders is important,
and prompt referral to a pediatric hepatology unit is essential.
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